Overview of Fabry Disease clinical features
Fabry disease is a rare, inherited lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase A. This enzyme deficiency leads to the accumulation of globotriaosylceramide (Gb3 or GL-3) within various cell types, resulting in a wide array of clinical manifestations that can affect multiple organ systems. Understanding the clinical features of Fabry disease is crucial for early diagnosis and management, which can significantly improve patient outcomes.
The onset of Fabry disease symptoms varies widely, often appearing in childhood or adolescence but sometimes not manifesting until adulthood. One of the earliest and most recognizable signs in males is acroparesthesias—burning or tingling sensations in the hands and feet—caused by small fiber neuropathy. Patients often describe these sensations as episodes of pain that can be triggered by fever, stress, or physical exertion. Alongside pain, patients may experience hypohidrosis or anhidrosis, a reduced or absent ability to sweat, which can further impair temperature regulation and increase susceptibility to heat-related discomfort.
Cutaneous manifestations are also prominent. Angiokeratomas—small, dark red to black raised skin lesions—are characteristic skin findings, typically localized in areas such as the umbilicus, groin, thighs, or lower abdomen. These lesions, although benign, serve as visible clues supporting the diagnosis, especially when combined with other systemic features.
As the disease progresses, it can affect the cardiovascular system. Patients may develop left ventricular hypertrophy, arrhythmias, and conduction abnormalities, which can lead to heart failure if left untreated. The accumulation of Gb3 in the endothelium and smooth muscle cells of blood vessels contributes to vascular dysfunction and increases the risk of cerebrovascular events such as strokes, often at a relatively young age in affected males.
Renal involvement is another significant aspect of Fabry disease. Proteinuria and progressive renal impairment are common, ultimately leading to chronic kidney disease or end-stage renal failure. The deposition of Gb3 in renal glomeruli, tubules, and vasculature underpins these renal pathologies. Early detection and treatment can slow renal deterioration and delay the need for dialysis or transplantation.
Ocular findings are also characteristic. Corneal verticillata, or whorl-like corneal deposits, are present in most patients and are often asymptomatic, serving as a key diagnostic feature when observed during slit-lamp examination. Other ocular signs, such as posterior spoke-like cataracts, may also be seen.
In addition to these systemic features, some patients may experience gastrointestinal symptoms like abdominal pain, diarrhea, or nausea due to Gb3 accumulation in the gastrointestinal tract. Hearing loss and tinnitus are less common but have been reported in some cases.
In summary, Fabry disease presents with a constellation of clinical features that affect multiple organ systems. The variability in presentation, especially between males and females—owing to its X-linked inheritance—can make diagnosis challenging. Recognizing the early signs, including acroparesthesias, skin lesions, and ocular changes, alongside potential cardiac and renal involvement, is vital for timely intervention. Enzyme replacement therapy (ERT) and emerging treatments aim to reduce Gb3 accumulation, alleviate symptoms, and prevent irreversible organ damage, emphasizing the importance of early diagnosis based on clinical features.
